Abstract Number: 1492 • ACR Convergence 2023
Pre-treatment Differentially Expressed Metagenes Characterize Systemic Lupus Patients Who Subsequently Achieve Clinical Response to Belimumab
Background/Purpose: Belimumab, which targets the B Cell activator and survival factor BLyS, is an approved treatment for systemic lupus (SLE) and has demonstrated efficacy in…Abstract Number: 1387 • ACR Convergence 2023
Power Doppler Musculoskeletal Abnormalities in Patients with Psoriasis at High Risk of Progression to Psoriatic Arthritis
Background/Purpose: Psoriatic arthritis (PsA) is an immune-mediated disease associated with skin psoriasis that, if untreated, can lead to joint destruction. Up to 30% of patients…Abstract Number: 1494 • ACR Convergence 2023
The Effect of Belimumab on Steroid Use in Patients with SLE: Results from a Retrospective Observational Study of Real-World Data from a US Rheumatology Provider Network
Background/Purpose: While oral CS (OCS) are the mainstay of SLE therapy, prolonged use is associated with organ damage and early mortality.1,2 Minimizing OCS use is…Abstract Number: 1462 • ACR Convergence 2023
Cardiovascular Damage in Systemic Lupus Erythematosus Occurs at Early Stages of the Disease. Chronological Analysis of Damage Accrual in a Large Cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER)
Background/Purpose: Systemic Lupus Erythematosus (SLE) survival has improved during recent decades, so other outcomes like damage accrual become more relevant. Damage represents that clinical feature…Abstract Number: 1403 • ACR Convergence 2023
MRI-defined Sacroiliitis in First Degree Relatives of Ankylosing Spondylitis Patients
Background/Purpose: Sacroiliitis is a main radiographic finding in axial spondyloarthritis (axSpA) - the inflammatory rheumatic disease with a strong genetic background. The aim of this…Abstract Number: 0903 • ACR Convergence 2023
Effects of Hydroxychloroquine on Maternal Outcomes in Pregnant Patients with Systemic Lupus Erythematous
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease, that affects women of childbearing age. SLE is a high-risk condition in pregnant patients due…Abstract Number: 1137 • ACR Convergence 2023
Association Between Nailfold Videocapillaroscopy Findings and sKL-6 Levels in Patients with Idiopathic Inflammatory Myopathies–Related Interstitial Lung Disease
Background/Purpose: Interstitial lung disease (ILD) is a frequent pulmonary manifestation in idiopathic inflammatory myopathies (IIM) (IIM-ILD) and considerably influences morbidity and mortality. Krebs von den…Abstract Number: 1396 • ACR Convergence 2023
Comprehensive Evaluation of the Digital Annular Pulleys: From Ultrasonographical to Anatomical and Histological Evaluation with Special Focus on the Entheses
Background/Purpose: The digital annular pulleys (DAP) are anatomical structures of soft connective tissue organized as transverse fibers of variable width, thickness, and configuration that overlay…Abstract Number: 0976 • ACR Convergence 2023
Sarcopenia and All-Cause Mortality in US Adults with and Without Rheumatoid Arthritis
Background/Purpose: Sarcopenia, which refers to the loss of muscle strength and mass, has been linked to adverse health outcomes. Although several systemic reviews have reported…Abstract Number: 0361 • ACR Convergence 2023
Safety of Golimumab Dose Escalation in Pediatric Autoimmunity: A Single Institution Retrospective Experience
Background/Purpose: There is limited data on pediatric golimumab dose escalation, with some data available only in the adult literature. The subcutaneous formulation is not approved…Abstract Number: 0802 • ACR Convergence 2023
Targeting Fibroblasts in Inflammatory Disease Using Engineered T Cells
Background/Purpose: Fibroblast activation protein alpha (FAPa) expressing fibroblasts orchestrate tissue inflammation and damage in rheumatoid arthritis (RA) as well as tissue immunity in primary Sjögren's…Abstract Number: 1504 • ACR Convergence 2023
Characteristics and Prior Treatment Journey of Systemic Lupus Erythematosus (SLE) Patients Who Were Prescribed Anifrolumab — Observations from the American Rheumatology Network (ARN) in the U.S
Background/Purpose: FDA-approved for moderate-severe SLE in August 2021, anifrolumab is a type I interferon (IFN) receptor antagonist that has been shown to decrease lupus flares…Abstract Number: 1505 • ACR Convergence 2023
Long-term Safety and Efficacy of Voclosporin in Black Patients with Lupus Nephritis: Results from the AURORA 1 and AURORA 2 Studies
Background/Purpose: Black patients with lupus nephritis (LN) are reported to have more severe disease, are often refractory to treatment, and have worse long-term outcomes. Voclosporin…Abstract Number: 1398 • ACR Convergence 2023
A Deep Learning Algorithm for MRI Spinal Inflammation in Axial Spondyloarthritis
Background/Purpose: Deep learning has achieved wide applications in different areas of medical imaging analysis. Limited studies have explored the use of deep learning for imaging…Abstract Number: 1148 • ACR Convergence 2023
A Comparative Study of Clinical Phenotype in Relation to NOD2 Sub-genotypes in Yao Syndrome
Background/Purpose: Yao syndrome (YAOS, OMIM 617321) is formerly designated NOD2-associated autoinflammatory disease. A spectrum of NOD2 mutations have been associated with this disease. Most patients…
- « Previous Page
- 1
- …
- 263
- 264
- 265
- 266
- 267
- …
- 2425
- Next Page »